Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155

Wednesday, July 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

WASHINGTON and WELLESLEY, Mass., July 29 Xceed Molecular,a pioneer in the development of cost-effective, easy-to-usegene-expression analysis systems, will launch its new Inflammation XpressChip, a pre-configured array for use with the company's Ziplex automatedgene-expression analysis system, at the 2008 AACC/ASCLS Clinical Lab Expo(booth 2155). The Clinical Lab Expo opens today at Walter E. WashingtonConvention Center in Washington, DC.

"With our expanding portfolio of Xpress Chips, Xceed is creating anotherbuilding block to accelerate the development of novel multiplex tests," saidXceed President and CEO David Deems. "Inflammation is a complex biologicalresponse to a wide range of tissue injuries, harmful pathogens, and disorders.This response is usually associated with increased levels of cytokines,cytokine receptors, adhesion molecules, and other immuno-regulatory factors.Our Inflammation Xpress Chip is a powerful tool to enable investigators todiscover and characterize molecular profiles associated with inflammatoryresponses, to study the effects of therapeutics in mitigating immuneresponses, and to study auto-immune diseases in general. Expression changes inspecific genes and pathways represented on the Inflammation Xpress Chip mayhelp in monitoring patient responses to therapy or in predicting the abilityof a therapeutic (e.g. Methotrexate, a TNF-alpha inhibitor, or a novelmonoclonal antibody-based compound) to block disease-related inflammationevents. The Inflammation Xpress Chip gene list was identified from scientificreports of genes differentially expressed in common inflammatory conditions.

At the core of the Ziplex System is the TipChip - a single-use disposabledevice consisting of a square Flow-Thru Chip(R) mounted to a polycarbonatetube. Unlike two-dimensional arrays, the unique 3D Flow-Thru Chip designenables active transport of targets to probes. Molecular interactions occurwithin the three-dimensional matrix of these channels as target solutions passthrough. The chip is made of porous silicon with microchannels that extendfrom the upper to the lower surface of the chip. Capture reagents are attachedto the walls of distinct groups of microchannels ("spots") and targetmolecules are captured as sample flows through the channels. Multiple capturereagents are deposited in a grid to permit parallel analysis of up to 484spots per chip ("features"). This approach facilitates the interaction betweentarget molecules and immobilized probes, resulting in hybridization times thatare three- to four-times faster.

Xceed offers two types of TipChips - preconfigured (Xpress Chips) andcustom (Autograph Chips(TM)). Xceed's preconfigured Xpress Chips (like the newInflammation Xpress Chip) contain published genes of interest for commonpathways or disease processes. They provide a ready-made solution, forresearch only, to assess specific transcript profiles. Xceed offers severalpreconfigured arrays. Xceed's Metabolic Xpress Chip offers genes of interestfor investigators exploring metabolic pathways and can be used to investigatedifferential expression associated with diseases of the metabolic system, suchas obesity, muscle disorders, and other metabolic disorders. Xceed also offersthe Breast and Colon Cancer Xpress Chips, and we have a number of otherTipChip arrays in development for a range of cancers, including prostate,lung, and melanoma. Xceed manufactures custom Autograph Chips with thecustomer's specific gene signatures of interest. Each array is ideal forfocused disease biomarkers comprising up to 120 genes, allowing for threereplicates per probe. Focused content allows cost-effective analysis ofrelevant markers in disease-process research investigations.

About Xceed Molecular (www.XceedMolecular.com)

Xceed's vision is to advance molecular diagnostics by successfullytranslating novel multiplex tests into routine clinical pract

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store